Brief: Shenzhen Hepalink Pharmaceutical Says Unit Got Approval Notice Of Supplementary Drug Application
26/10/2020 13:37
Oct 26 (Reuters) - Shenzhen Hepalink Pharmaceutical Group Co
Ltd 002399.SZ :
* UNIT GOT NOTICE OF APPROVAL OF SUPPLEMENTARY DRUG
APPLICATION
ISSUED BY NMPA
* ANNOUNCES PASSING OF CONSISTENCY EVALUATION FOR GENERIC
DRUG OF
ALL STRENGTHS OF "ENOXAPARIN SODIUM INJECTION"
Source text for Eikon: ID:nHKSbhN5mp
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA